articleThe Lancet OncologyDec 9, 2009Closed access

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Memorial Sloan Kettering Cancer Center · Universitair Ziekenhuis Brussel · +15 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,186
total citations
FWCI
26.54
Percentile
100%
References
29
Citations per year

Authors

17

Topics & keywords

Keywords
  • Medicine
  • Ipilimumab
  • Adverse effect
  • Clinical endpoint
  • Internal medicine
  • Melanoma
  • Clinical trial
  • Intention-to-treat analysis
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.